A diagnosis of kidney cancer, also known as renal cancer, requires strong partnership with your oncologist. This overview is ...
Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study. Efficacy outcomes with belzutifan versus everolimus by ...
Researchers at London Health Sciences Center Research Institute (LHSCRI) have launched a Phase II clinical trial that aims to ...
As September concludes, the landscape of GU oncology continues to evolve, with important developments in prostate, bladder, ...
For patients with primary localized renal cell carcinoma (RCC), especially those who aren’t good candidates for surgery, noninvasive or minimally invasive ablative treatments have emerged as important ...
Circulating tumor DNA (ctDNA) is emerging as a promising biomarker to predict treatment response in patients with metastatic renal cell carcinoma (mRCC). In a recent study, Alan Tan, MD, of Vanderbilt ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...
The impact of nephrectomy on the clinical outcomes of first-line immunotherapy and tyrosine kinase inhibitors combinations versus sunitinib in advanced renal cell carcinoma: A meta-analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback